Prevalence, Incidence and Etiology of Hyponatremia in Elderly Patients with Fragility Fractures

Kirsten Cumming¹, Graeme E. Hoyle¹, James D. Hutchison², Roy L. Soiza¹*
¹ Acute Geriatric Medicine, Aberdeen Royal Infirmary, Aberdeen, United Kingdom, ²Surgery and Orthopaedics, University of Aberdeen Medical School, Aberdeen, United Kingdom

Abstract

Introduction: Hyponatremia (serum sodium <135 mMol/L) is the commonest electrolyte imbalance encountered in clinical practice. It is associated with multiple poor clinical outcomes including increased mortality, longer hospital stay, falls and fractures. Prevalence is higher in frail patient groups, and elderly patients with fragility fractures (EPFF) are particularly susceptible. Euvolemic hyponatremia due to syndrome of inappropriate anti-diuretic hormone (SIADH) is widely assumed to be the commonest cause. However, little is known about the epidemiology and etiology of hyponatremia in EPFF. This study established prevalence, incidence and etiology of hyponatremia in EPFF.

Methods: Prospective observational study of consenting adults aged ≥65 years admitted with a fragility fracture to a university hospital between 7th January and 4th April 2013. Prevalence of hyponatremia on admission and incidence of cases developing in hospital were reported. Etiology of cases of hyponatremia was determined by consensus of an expert panel using pre-specified data collected daily.

Results: 127/212 (60%) EPFF were recruited (mean age 79 yrs, 78% female). Two participants withdrew mid-study. Of those not recruited, 66 had incapacity to consent and 19 refused participation. Point prevalence of hyponatremia on admission was 13.4% and a further 12.6% developed hyponatremia during admission. Hypovolemic hyponatremia was predominant (70%). 73% of cases were multi-factorial in etiology. The commonest potentially causative factors in cases of hyponatremia were thiazide diuretics (76%), dehydration (70%), proton pump inhibitors (70%), SIADH (27%) and mirtazapine (15%).

Conclusion: Hyponatremia is highly prevalent in EPFF, seen in 26% of cases. Dehydration and prescription of thiazide diuretics and proton pump inhibitors were the commonest potentially causative factors, not SIADH.

Introduction

Hyponatremia, serum sodium < 135 mMol/L, is the commonest electrolyte imbalance encountered in clinical practice. It is associated with multiple poor clinical outcomes including falls, fractures, increased length of hospital stay, institutionalisation and mortality [1]. Prevalence is known to increase in frail patient groups, such as elderly, hospitalised, peri-operative patients with a fracture. Elderly patients with fragility fractures (EPFF) have increased risk of hyponatremia as a result of degenerate physiology, multiple co-morbidities, polypharmacy, increased risk of dehydration due to hospitalisation and peri-operative fluid restriction, and homeostatic stress from fracture and subsequent surgical interventions [2–6]. They are also at higher risk of complications, making this group of special clinical importance. Hyponatremia itself may be responsible for the fracture [7]. Reports of the prevalence of hyponatremia at admission in EPFF vary widely between 2.8%–26.5%, while 2.6–5.5% develop hyponatremia in the post-operative period [3–5,8,9]. Hyponatremia occurs due to disruption of sodium and water homeostasis, normally maintained by complex multi-system physiological mechanisms [1]. Consequently, there are numerous potential underlying causes of hyponatremia, spanning a broad spectrum of diseases, pharmacotherapy and pathophysiological variants each with different treatment requirements (see Figure 1) [2].

When very acute or severe, hyponatremia may present with neurological symptoms which can result in serious complications e.g. hyponatremic encephalopathy, non-cardiogenic pulmonary oedema, seizures, coma, death [2,10–13]. However, 75–80% of cases of hyponatremia are mild and chronic (i.e. serum sodium 130–134 mMol/L, occurring over >24 hours) and typically devoid of obvious neurological symptoms [1,2,14]. As a result, chronic mild hyponatremia is frequently considered asymptomatic despite being strongly associated with major geriatric conditions and multi-organ pathological changes. These include abnormal gait patterns, falls, fractures, cognitive impairment, bone demineralisation, longer hospital stay, institutionalisation and increased mortality [2,5,6,9,12,15–19]. Despite this, older people may be at lower risk of hyponatremic encephalopathy and subsequent complications of acute severe hyponatremia [20], where female...
gender, hypoxia and liver dysfunction are associated with poorer prognosis [21]. Whether hyponatremia is an independent predictor of patient outcomes or a marker of disease severity is controversial [2]. Nevertheless, it is very treatable, so its association with multiple poor clinical outcomes is important.

Clinical management of hyponatremia is based on diagnosing and treating the underlying cause(s) and restoring salt and water balance (see Figure 2) [1]. However, accurate determination of etiology of hyponatremia is notoriously challenging [22]. The best available method to elucidate causes of hyponatremia is by expert panel consensus. Diagnosis depends crucially on accurate assessment of volemic status which is difficult to determine with certainty, especially in older individuals for whom there is currently no reliable biomarker of hydration [2,20]. Euvolemic hyponatremia due to the syndrome of inappropriate antidiuretic hormone (SIADH) is widely assumed to be the commonest cause [17]. However, SIADH may be over-diagnosed as a result of diagnostic difficulties, particularly in dehydrated older people [2,23]. Subsequently, patients may be subject to serious clinical consequences as the management of SIADH (fluid restriction) is the exact opposite of the management of dehydration (vigorous fluid replacement).

SIADH is a reportedly common cause of hyponatremia in EPFF along with excess hypotonic fluid, diuretic and antidepressant therapies [3,5,8–10], but the process of attribution of causation of hyponatremia in these studies did not include expert review or any quality assurance process. Our aim was to undertake the most detailed study to date of the etiology of hyponatremia in EPFF and report its prevalence and incidence.

Materials and Methods

We carried out a prospective observational study of all adults aged 65 years or over admitted with a fragility fracture to a university teaching hospital from 7th January – 4th April 2013. Fragility fractures were defined as those occurring either without trauma or due to low energy trauma, equivalent to a fall from standing height or less than one metre. Anonymous baseline data (age, sex, fracture site and admission serum sodium) of all identified EPFF were recorded. Adults with incapacity were excluded from recruitment. Capacity to consent was assessed by the attending clinical team in accordance with the Adults with Incapacity (Scotland) Act 2000. Participants were recruited from acute orthopaedic trauma wards and a geriatric assessment unit. Clinical data were collected daily until discharge, from patient interview, medical and nursing notes, observation and fluid balance charts and laboratory computer systems by a single investigator (KC). Medication data were obtained by reconciling patient and/or carer histories, and primary and secondary care records. Also, clinical examination of volemic status was performed daily by the investigator. This involved measurement of skin turgor, capillary refill time, mouth moistness, axillary
The proportion of participants with known hyponatremia at discharge was 19%. Thus, hyponatremia upon admission in all identified EPFF was 14.2%. In recruited volunteers, the prevalence of known hyponatremia prior to their fracture was 10.2%. Point prevalence at admission in the recruited group was 13.4%. There were 16 incident cases of hyponatremia developing in hospital (12.6%). Of these incident cases, four (25%) developed pre-operatively, eleven (68.8%) post operatively (one patient died), and one (6.3%) in a patient who was deemed unfit for surgery. The prevalence of known hyponatremia at discharge was 19%. Thus, hyponatremia was detected in 33 participants (26%) and mild hyponatremia (Na 130–134 mmol/L) was predominant (N = 25, 75.8%).

Etiology of hyponatremia

Hypovolemic hyponatremia was present in 23 cases (69.7%), 9 cases were euvolemic (27.3%) and one case hypervolemic (3%). Etiology was multifactorial in 24/33 cases (72.7%). The identified underlying causes and contributory factors are displayed in Table 4. There were no significant differences in causes of hyponatremia between those developing pre- or post-admission.

Figure 2. Participant recruitment flow chart.
doi:10.1371/journal.pone.0088272.g002

moistness, jugular venous distension, peripheral oedema and overall impression (signs selected based on previous research recommendations) [22]. Examination was carried out by one investigator to increase reliability of findings, maximise consistency and exclude effects of inter-observer variability. An initial two week training period of examination of volemic status, under supervision of the principal investigator (RLS), was undertaken to help ensure quality and consistency.

Cases of hyponatremia were defined as any serum sodium measurement <135 mmol/L. An expert panel, consisting of two consultant geriatricians with special interest in hyponatremia (RLS and GEH) and one consultant orthopaedic surgeon (JDH) reviewed and determined etiology of each case of hyponatremia. The panel did not examine patients themselves but instead retrospectively reviewed each case of hyponatremia relying on the detailed daily prospectively-collected data and clinical examination findings provided by the investigator. This included all clinical information required to determine underlying cause(s) of hyponatremia - history, medications, detailed daily examination, fluid intake and output charts and laboratory results. Collectively, the expert panel used a diagnostic algorithm (Figure 1) to determine underlying cause(s) of hyponatremia.

Ethical approval was obtained from the Scotland A Research Ethics Committee (Ref 12/SS/0209). The original protocol submitted to the Committee had provision for the inclusion of adults with incapacity to consent but the Committee’s approval was dependent on their exclusion. The Committee’s recommendations were fully incorporated into the final study design and final approval was obtained from the Committee Scientific Advisor.

The prevalence of hyponatremia upon admission and the incidence of cases developing in hospital were calculated. For incident cases, we recorded whether the hyponatremia was pre- or post-operative. The proportion of participants with known hyponatremia prior to their fracture was calculated by obtaining

the last available serum sodium for each patient prior to their admission to hospital. The laboratory is the only public health service laboratory covering the study population so it was unlikely that patients had more recent investigations elsewhere. Prevalence of hyponatremia at discharge was calculated according to the last available serum sodium measurement prior to discharge.

Independent-T tests or Mann-Whitney U tests were used as appropriate. Pearson chi-squared and Fisher’s exact tests were calculated to compare proportions across groups. Statistical Package for Social Sciences (SPSS) version 20.0 was used to perform all analyses. Statistical significance was assumed where p<0.05.

Results

Recruitment, participant information and data collection

There were 214 EPFF identified and 127 were recruited into the study (see Figure 2). Those not recruited had incapacity to consent (N = 66), declined participation (N = 19), or agreed but were later excluded when the original diagnosis of fragility fracture was excluded (N = 2). There were no statistically significant differences between participants and those who were eligible but declined participation (see Table 1). However, compared to participants, adults with incapacity were on average seven years older (p < 0.001) and had different proportions of fractures site, with hip fractures composing n = 47 (71.2%) of fractures compared to n = 67 (52.8%) in participants (p = 0.017). The characteristics and outcomes of the 127 participants are detailed in Tables 2 and 3, categorised according to natremic state.

Two (1.6%) participants voluntarily withdrew mid-study, but all others completed the study (n = 125). Data completion was 86% overall as daily clinical examination was not always appropriate or possible (e.g. patient declining on a given day or in critical condition). Although all volunteers had at least one serum sodium and at least 24 hours of fluid balance measurements, serum sodium measurements were available in 44% of the total patient-days in hospital. Complete fluid balance charts were available for 50% of the total days spent in hospital by participants. Medication data were complete for all cases. None of the hyponatremic participants had urine sodium concentration measured.

Epidemiology of hyponatremia

Prevalence of hyponatremia upon admission in all identified EPFF was 14.2%. In recruited volunteers, the prevalence of known hyponatremia prior to their fracture was 10.2%. Point prevalence at admission in the recruited group was 13.4%. There were 16 incident cases of hyponatremia developing in hospital (12.6%). Of these incident cases, four (25%) developed pre-operatively, eleven (68.3%) post operatively (one patient died), and one (6.3%) in a patient who was deemed unfit for surgery. The prevalence of known hyponatremia at discharge was 19%. Thus, hyponatremia was detected in 33 participants (26%) and mild hyponatremia (Na 130–134 mmol/L) was predominant (N = 25, 75.8%).

Etiology of hyponatremia

Hypovolemic hyponatremia was present in 23 cases (69.7%), 9 cases were euvolemic (27.3%) and one case hypervolemic (3%). Etiology was multifactorial in 24/33 cases (72.7%). The identified underlying causes and contributory factors are displayed in Table 4. There were no significant differences in causes of hyponatremia between those developing pre- or post-admission.
The findings demonstrate that hyponatremia in EPFF is highly prevalent, occurring in 33/127 cases (26%). Although it had previously been assumed that euvolemic hyponatremia is the commonest type, this study shows that hypovolemic hyponatremia is predominant in EPFF.

The 13.4% point prevalence of hyponatremia upon hospital admission, is within the range of recently reported figures for EPFF, 2.8–26.5% [5,8,9,24–26]. Our result is almost identical to that of Gankam Kengne et al. who report 13.1% prevalence in EPFF, studying a population with similar proportions of hip and femoral fractures (55%) in a larger scale retrospective study [5].

The 10.2% prevalence of hyponatremia prior to fracture in this study is higher than the 8% prevalence reported in ambulatory patients 60 years and 5.7% in very old non-hospitalised individuals [4,27]. This may reflect the underlying frailty of those that go on to sustain fragility fractures but is also consistent with the theory that some fractures may be attributable to hyponatremia [7,16]. The 12.6% incidence of hyponatremia developing in hospital reported here is significantly higher than previous accounts in EPFF, which range from 2.6 to 5.5% [3,8,24,28]. However, unlike previous authors, we reported cases of hyponatremia developing at any stage in hospital rather than solely in the post-operative period. The high incidence of new hyponatremia has important implications for patient welfare as patients who develop hyponatremia in hospital reportedly fare worse than those who are hyponatremic on admission [6,29,30]. The prevalence of hyponatremia at discharge was 19%. There are few data in the current literature to compare our figure with. However, it appears common practice not to treat hyponatremia, particularly when mild and chronic, so the prevalence of hyponatremia at discharge is presumably high [5,31,32]. This implies that clinician awareness of the potential dangers of hyponatremia is low. Gankam Kengne et al. reported that four of eighteen EPFF discharged with hyponatremia had recurrent falls and fractures [5]. In common with comparable studies, most cases of hyponatremia in this study were mild and therefore at risk of being unidentified or ignored [16,25,33].

Regarding etiology, hyponatremia was multi-factorial in 72.7% of cases in this study. This is consistent with previous reports that 51.3% and 75.3% of hyponatremia in elderly patients is multifactorial, though both reports concerned severe hyponatremia [18,19]. However, our findings contrast with previous studies that report that SIADH is the commonest cause of hyponatremia in other patient settings [18,19]. SIADH was associated with 27.3% of cases of hyponatremia in this study. In a most similar cohort of EPFF, 37% of cases of hyponatremia were attributed to SIADH on discharge diagnosis, all of which were idiopathic [5]. Although SIADH may have no obvious underlying cause, this raises the possibility that SIADH was over-diagnosed [21]. The findings of our study suggest that SIADH is not the commonest cause of hyponatremia in EPFF and that causes related to hypovolemia are more frequent.

Thiazide diuretic therapy (bendroflumethiazide in all instances) was a causative factor in 75.8% of cases of hyponatremia. It was a causative factor in 75.8% of cases of hyponatremia. This high prevalence is greater than that reported in any other series, but is consistent with recent findings that thiazide diuretic therapy is an increasingly important cause [34–35]. Gankam Kengne et al. reported diuretics were associated with 35% of cases of hyponatremia in EPFF [5]. Hoorn et al. observed a higher prescription frequency in hyponatremic EPFF compared to normonatremic controls [33]. In our study, bendroflumethiazide therapy was three times more commonly prescribed in hyponatremic

| Number of individuals (N) | Participants | Non-participants | P value* | Adults with incapacity | P value** |
|---------------------------|-------------|-----------------|----------|------------------------|----------|
| Age (years)               |             |                 |          |                        |          |
| Mean (± SD)               | 79 (±8)     | 77 (±9)         | 0.438    | 86 (±7)                | <0.001   |
| Range                     | 65–98       | 65–93           |          | 66–101                 |          |
| Female sex, % (N)         | 78.0 (99)   | 89.5 (17)       | 0.365    | 69.7 (46)              | 0.223    |
| Fracture site, % (N)      |             |                 |          |                        |          |
| Hip                       | 52.0 (66)   | 36.8 (7)        |          | 69.7 (46)              |          |
| Hip & upper limb          | 0.8 (1)     | 0               | 1.5 (1)  | 0                      |          |
| Other lower limb          | 22.0 (28)   | 31.6 (6)        | 7.6 (5)  | 0                      |          |
| Other lower & upper limb  | 0.8 (1)     | 0               | 0        | 0                      |          |
| Upper limb                | 19.7 (25)   | 26.3 (5)        | 10.6 (7) | 0                      |          |
| Pelvic and upper limb     | 0           | 0               | 1.5 (1)  | 0                      |          |
| Pelvic                    | 3.1 (4)     | 5.3 (1)         | 6.1 (4)  | 0                      |          |
| Vertebral                 | 1.6 (2)     | 0               | 3.3 (2)  | 0                      |          |
| Admission serum sodium (mMol/L) |            |                 |          |                        |          |
| Mean (± SD)               | 138 (±4)    | 138 (±5)        | 0.556    | 139 (±4)               | 0.172    |
| Range                     | 123–146     | 128–143         | 124–147  |                        |          |
| Prevalence of hyponatremia on admission, % (N) | 13.4 (17) | 26.3 (5) | 0.16 | 12.1 (8) | 0.827 |

*participants v non-participants. **participants v adults with incapacity.

doi:10.1371/journal.pone.0088272.t001

Table 1. Subgroup analysis of baseline data.

Discussion

The findings demonstrate that hyponatremia in EPFF is highly prevalent, occurring in 33/127 cases (26%). Although it had previously been assumed that euvolemic hyponatremia is the commonest type, this study shows that hypovolemic hyponatremia is predominant in EPFF.

The 13.4% point prevalence of hyponatremia upon hospital admission, is within the range of recently reported figures for EPFF, 2.8–26.5% [3,8,9,24–26]. Our result is almost identical to that of Gankam Kengne et al. who report 13.1% prevalence in EPFF, studying a population with similar proportions of hip and femoral fractures (55%) in a larger scale retrospective study [5]. The 10.2% prevalence of hyponatremia prior to fracture in this study is higher than the 8% prevalence reported in ambulatory patients >60 years and 5.7% in very old non-hospitalised individuals [4,27]. This may reflect the underlying frailty of those that go on to sustain fragility fractures but is also consistent with the theory that some fractures may be attributable to hyponatremia [7,16]. The 12.6% incidence of hyponatremia developing in hospital reported here is significantly higher than previous accounts in EPFF, which range from 2.6 to 5.5% [3,8,24,28]. However, unlike previous authors, we reported cases of hyponatremia developing at any stage in hospital rather than solely in the post-operative period. The high incidence of new hyponatremia has important implications for patient welfare as patients who develop hyponatremia in hospital reportedly fare worse than those who are hyponatremic on admission [6,29,30]. The prevalence of hyponatremia at discharge was 19%. There are few data in the current literature to compare our figure with. However, it appears common practice not to treat hyponatremia, particularly when mild and chronic, so the prevalence of hyponatremia at discharge is presumably high [5,31,32]. This implies that clinician awareness of the potential dangers of hyponatremia is low. Gankam Kengne et al. reported that four of eighteen EPFF discharged with hyponatremia had recurrent falls and fractures [5]. In common with comparable studies, most cases of hyponatremia in this study were mild and therefore at risk of being unidentified or ignored [16,25,33].

Regarding etiology, hyponatremia was multi-factorial in 72.7% of cases in this study. This is consistent with previous reports that 51.3% and 75.3% of hyponatremia in elderly patients is multifactorial, though both reports concerned severe hyponatremia [18,19]. However, our findings contrast with previous studies that report that SIADH is the commonest cause of hyponatremia in other patient settings [18,19]. SIADH was associated with 27.3% of cases of hyponatremia in this study. In a most similar cohort of EPFF, 37% of cases of hyponatremia were attributed to SIADH on discharge diagnosis, all of which were idiopathic [5]. Although SIADH may have no obvious underlying cause, this raises the possibility that SIADH was over-diagnosed [21]. The findings of our study suggest that SIADH is not the commonest cause of hyponatremia in EPFF and that causes related to hypovolemia are more frequent.

Thiazide diuretic therapy (bendroflumethiazide in all instances) was a causative factor in 75.8% of cases of hyponatremia. It was a causative factor in 75.8% of cases of hyponatremia. This high prevalence is greater than that reported in any other series, but is consistent with recent findings that thiazide diuretic therapy is an increasingly important cause [34–35]. Gankam Kengne et al. reported diuretics were associated with 35% of cases of hyponatremia in EPFF [5]. Hoorn et al. observed a higher prescription frequency in hyponatremic EPFF compared to normonatremic controls [33]. In our study, bendroflumethiazide therapy was three times more commonly prescribed in hyponatremic
EPFF (21.2%) than in normonatremic EPFF (7.4%) \( (p = 0.049) \). This is an important finding given the high prevalence of hypertension in elderly people and the widespread prescribing of thiazide diuretics [34,35].

Dehydration was associated with 69.7% of hyponatremia, which is in keeping with our previous proposition that many hyponatremic older individuals have appropriate ADH secretion and are, in fact, inadequately hydrated [21]. Dehydration was the result of over-use or incorrect use of diuretics, or inadequate fluid

### Table 2. Participant characteristics.

| Characteristic                                                                 | Normonatremic participants | Hyponatremic participants | P value |
|-------------------------------------------------------------------------------|----------------------------|---------------------------|---------|
| Number (N)                                                                    | 94                         | 33                        |         |
| **Age (years)**                                                               |                            |                           |         |
| Mean (± SD)                                                                   | 78 (±8)                    | 81 (±7)                   | 0.083   |
| Range                                                                         | 65–97                      | 69–98                     |         |
| **Female sex, % (N)**                                                         |                            |                           |         |
| Own home                                                                      | 85.1 (80)                  | 78.8 (26)                 | 0.390   |
| Sheltered housing                                                             | 14.9 (14)                  | 12.1 (4)                  |         |
| Care home                                                                     | 0                          | 6.1 (2)                   |         |
| Care of the elderly ward                                                      | 0                          | 3.0 (1)                   |         |
| **Number of co-morbidities**                                                  |                            |                           |         |
| Mean (± SD)                                                                   | 4 (±2)                     | 5 (±3)                    | 0.222   |
| Range                                                                         | 0–9                        | 0–11                      |         |
| **Number of co-morbidities that cause hyponatremia (N)**                     |                            |                           |         |
| Mean (± SD)                                                                   | 1 (±1)                     | 1 (±1)                    | 0.855   |
| Range                                                                         | 0–3                        | 0–4                       |         |
| % of participants with at least one co-morbidity that causes hyponatremia (N)| 60.6 (57)                  | 54.5 (18)                 | 0.681   |
| **Number of medications (N)**                                                |                            |                           |         |
| Mean (± SD)                                                                   | 5 (±4)                     | 6 (±3)                    | 0.294   |
| Range                                                                         | 0–15                       | 0–15                      |         |
| % of participants on at least one medication that causes hyponatremia (N)     | 64.9 (61)                  | 72.7 (24)                 | 0.52    |
| **Fracture site, % (N)**                                                      |                            |                           | 0.115   |
| Hip                                                                           | 50.0 (47)                  | 57.6 (19)                 |         |
| Hip and upper limb                                                            | 1.1 (1)                    | 0                         |         |
| Other lower limb                                                              | 24.5 (23)                  | 15.2 (5)                  |         |
| Other lower limb and upper limb                                               | 0                          | 3.0 (1)                   |         |
| Upper limb                                                                    | 21.3 (20)                  | 15.2 (5)                  |         |
| Pelvic                                                                        | 3.3 (3)                    | 3.0 (1)                   |         |
| Vertebral                                                                     | 0                          | 6.1 (2)                   |         |
| **Time from fracture to hospital admission (days)**                           |                            |                           |         |
| Median                                                                        | 0                          | 0                         | 0.581   |
| Interquartile range                                                           | 0–1                       | 0–1.5                     |         |
| **Serum sodium prior to admission (mMol/L)**                                  |                            |                           |         |
| Mean (± SD)                                                                   | 140 (±2)                   | 136 (±5)                  | <0.001  |
| Range                                                                         | 133–145                    | 127–144                   |         |
| **Serum sodium on admission (mMol/L)**                                        |                            |                           |         |
| Mean (± SD)                                                                   | 139 (±2)                   | 134 (±4)                  | <0.001  |
| Range                                                                         | 135–146                    | 127–144                   |         |
| **Prevalence of hyponatremia, % (N)**                                          |                            |                           |         |
| Prior to admission*                                                           | 3.2 (3)                    | 30.3 (10)                 | <0.001  |
| On admission*                                                                 | 0                          | 51.5 (17)                 | <0.001  |

*According to last serum sodium available prior to admission.

doi:10.1371/journal.pone.0088272.t002
inadequate fluid and electrolyte management in elderly surgical patients is not a new concern, the prevalence and importance of dehydration in hyponatremia and EPFF is relatively unreported. Absence of reports may stem from the frequent retrospective methodology approaches, reliant on clinical documentation which often lack any record of hydration state [32]. Given the high prevalence of co-morbidities and polypharmacy in EPFF, cases of hyponatremia caused by dehydration may be misattributed to other causes. Thus dehydration, arguably the simplest and most readily treatable etiology of hyponatremia, could be frequently over-looked and underdiagnosed. This study shows it is a major cause of hyponatremia in EPFF.

Proton pump inhibitor (PPI) therapy (omeprazole in all cases in our study) was associated with 69.7% of cases of hyponatremia. To our knowledge we are the first group to present this finding in EPFF. Reports of omeprazole induced hyponatremia are infrequent and our finding may simply reflect the very high prevalence of PPI prescribing in older hospitalised patients [36]. The prevalence of PPI therapy among hyponatremic patients was 42.4% compared to 35.1% in normonatremic patients (p = 0.51). Another possibility is that few cases of hyponatremia are solely attributable to PPIs but hyponatremia in EPFF is predominantly multifactorial [37]. Rosholm et al. report a lower mean serum sodium in very old non-hospitalised individuals prescribed omeprazole compared to controls and emphasise the role of degenerative physiology in adverse drug reactions [27]. Considering the likelihood of degenerative physiology in EPFF and the physiological stress in the post-fracture and peri-operative period, our finding that omeprazole may be a significant contributor to hyponatremia in EPFF is an important one that merits further study.

Antidepressants were commonly associated with hyponatremia in our study. The commonest in our cohort (15.2% of cases) was mirtazapine. Sertraline, and amitriptyline were both associated...
with a single case each (3%). Our findings are in line with those of other studies. Studying large bone fractures, Sandu et al. report that 24.2% of hyponatremic patients were prescribed antidepressants (75% selective serotonin reuptake inhibitors (SSRIs) and 25% mirtazapine), compared to no antidepressant prescriptions in a control group with no fracture [25]. Studying EPFF, Gankam Kenoge et al. similarly report that 17% of cases of hyponatremia were attributable to SSRIs. Previous studies present conflicting evidence between specific antidepressants and the risk of hyponatremia, and this may simply reflect differences in prescribing patterns [38,39]. Movig et al. report that, in elderly people, concomitant diuretic and SSRl therapy incurs a 15.5 increased odds ratio of developing hyponatremia compared to SSRI therapy alone [39]. The frequent concomitant prescribing of both these drug classes in elderly patients makes this an important observation, especially considering the results of our study.

The remaining etiologies encountered in this study were not surprising and were representative of a general multi-morbidity elderly patient cohort. Two independent groups reported that all elderly orthopedic patients becoming hyponatremic post-operatively received hypotonic fluids, mostly in the form of dextrose [3,40]. We did not find this in our study as hypotonic study was hardly ever prescribed (only to two patients that developed hyponatremia and no more than 1000 mls each in total). However, fluid overload was associated with one case of hyponatremia where the patient had cardiac failure (3%). This may reflect different practices in different centres or may reflect changes in practice with time.

We did not set out to measure outcomes in this study, but the mean length of time from admission to surgery was higher in hyponatremic participants (3 days) compared to normonatremic participants (1.8 days), a 66.7% increase (p = 0.014). This delay is a potential risk factor for development of hyponatremia and suggests patients with admission or pre-operative hyponatremia may have more complicated co-morbidities or fractures and therefore require a pre-operative preparatory period. It also suggests that a delayed time to surgery increases the risk of hyponatremia, potentially by dehydration or inappropriate fluid and electrolyte management. Hyponatremic participants had a 3.5 day longer mean length of hospital stay, compared to normonatremic participants, a 51.5% increase (p = 0.006). Delayed discharge in hyponatremic patients may be caused by attempts to correct the hyponatremia in hospital but it is clear from our study that this is not the case as asymptomatic hyponatremia was usually left untreated. More plausible alternative explanations are that the hyponatremia is a marker of dyshomeostasis or comorbidities which delay discharge, or directly causes subtle cognitive or functional impairments that complicate discharge.

Our study has some important limitations. The observational design did not permit the investigating team to request clinical tests. This was particularly relevant because the clinical management of hyponatremia was frequently sub-optimal and important clinical investigations were not always carried out. Therefore data were missing in some instances.

In these instances the expert panel relied on available clinical information and the over-all clinical picture of each case as it transpired i.e. changes in serum sodium compared to pre-genic interventions. This same limitation has previously been encountered by various other groups [5,31,32]. Since patients did not have daily serum sodium measurements, it is likely that our report may underestimate the true incidence of hyponatremia in EPFF. The same issue also complicated the already challenging task of diagnosing etiology of hyponatremia in elderly patients. Although expert panel consensus decision represents the best available method to elucidate causes, there remains considerable uncertainty with regard to diagnosis, especially where information is limited. This is particularly pertinent in relation to diagnosing SIADH, which strictly requires urine sodium concentration measurement and other investigations that are frequently missed [41]. Whilst these are limitations of this study they reflect the reality of inadequate awareness and management of hyponatremia in clinical practice, predisposing these already frail patients to worsened clinical outcomes.

A second limitation is the relatively small sample size of this single centred study meaning that the results may be subject to selection and sampling bias. Moreover adults with incapacity, who compose a significant proportion of EPFF, were excluded from this study as dictated by the ethics committee. Given the independent association between hyponatremia and age, excluding this frail patient cohort at highest risk of hyponatremia (mean age 7 years older than participants), compromises the generalisability of our findings [2]. Furthermore, considering the 12.1% prevalence of hyponatremia among the adults with incapacity identified in this study and the association between hyponatremia and cognitive impairment, including this patient subset in future research ought to be routine. Indeed, hyponatremia may be the precipitant cause of incapacity and so these frailer patients may arguably benefit most from improved understanding of etiology of hyponatremia in EPFF. A third limitation is the possibility of ascertainment bias as individual members of the expert panel may have their own preconceptions on common and uncommon causes. However, discussion amongst the three experts and the use of the diagnostic algorithm served to minimise ascertainment bias, if any was present.

Despite these limitations this study makes a significant contribution to the current understanding of hyponatremia in EPFF. The prospective study design is an improvement over published retrospective comparators. Unlike other published series that typically rely on diagnoses made by clinicians inexpert in hyponatremia, or on retrospective analysis of databases using discharge codes, the present study collected data prospectively that were then reviewed by an expert panel. The attention paid to data regarding volemic state in our study far surpasses previous work. Despite the aforementioned limitations, the involvement of two consultant geriatricians with special interest in hyponatremia, makes this report the most accurate account of etiology of hyponatremia in EPFF to date. The expertise of these individuals not only provided quality assurance of etiology reported for these complex patients, but enabled identification of the likeliest diagnoses in cases lacking all data.

In summary, hyponatremia is highly prevalent in EPFF. This study shows that etiology of hyponatremia in EPFF is frequently multifactorial, mostly drug induced and associated with inadequate fluid replacement therapy. We found SIADH was associated with under a third of cases. This suggests that prevalence and incidence of hyponatremia in EPFF could potentially be reduced by appropriate fluid replacement therapy and careful prescribing. It would be important to confirm this in a further larger, multi-centre study. Although it remains unclear if targeting hyponatremia itself would improve patient outcomes, such interventions have great potential to decrease falls and fractures in older people and generally improve prognosis in EPFF.

**Author Contributions**

Conceived and designed the experiments: RLS. Performed the experiments: KC GEH JDH RLS. Analyzed the data: KC RLS. Contributed reagents/materials/analysis tools: JDH RLS. Wrote the paper: KC GEH JDH RLS.
| References                                                                 |   |
|--------------------------------------------------------------------------|---|
| 1. Soiza RL, Hoyle GE, Chua MPW (2008) Electrolyte and salt disturbances |   |
| in older people: causes, management and implications. Rev Clin Gerontol  |
| 18:143–150.                                                              |   |
| 2. Soiza RL, Talbot HSC (2011) Management of hyponatraemia in older      |   |
| people: old threats and new opportunities. Ther Adv Drug Safety 2:9–17.   |   |
| 3. Tambe AA, Hill R, Livesley PJ (2003) Post-operative hyponatraemia    |   |
| in orthopaedic injury. Injury 34:253–255.                                 |   |
| 4. Upadhyay A, Jahe RL, Madhav NE (2006) Incidence and Prevalence of     |   |
| Hyponatraemia. Am J Med 119:S30–S35.                                     |   |
| 5. Gankam Kenague F, Andres C, Sattar L, Melot C, Decaux G (2008) Mild  |   |
| hyponatraemia and risk of fracture in the ambulatory elderly. QJM 101:583– |   |
| 588.                                                                     |   |
| 6. Chua M, Hoyle GE, Soiza RL (2007) Prognostic implications of          |   |
| hyponatraemia in elderly hospitalized patients. Arch Gerontol Geriatr 53: |   |
| 233–259.                                                                 |   |
| 7. Ayus JC, Arieff AI (1999) Chronic hyponatraemic encephalopathy in    |   |
| postmenopausal women: association of therapies with morbidity and        |   |
| mortality. JAMA 281:2299–2304.                                           |   |
| 8. Beloosesky Y, Hershkovitz A, Solovey B, Salai M, Weiss A. (2011) Hip  |   |
| fracture post-operation dysnatremia and Na+ courses in different        |   |
| cognitive and functional patient groups. Arch Gerontol Geriatr 53:179–   |   |
| 182.                                                                     |   |
| 9. Toloian R, Alhamad T, Faraazmand M, Mulla ZD (2012) The correlation   |   |
| of hip fracture and hyponatraemia in the elderly. J Nephrol 25:789–793.   |   |
| 10. Ayus JC, Krothapalli RK, Arieff AI (1987) Treatment of symptomatic    |   |
| hyponatraemia and its relation to brain damage. N Engl J Med 317:1190–1195. |   |
| 11. Ayus JC, Varon J, Arieff AI (2000) Hyponatraemia, cerebral edema,    |   |
| and noncardiogenic pulmonary edema in marathon runners. Ann Intern Med  |   |
| 132:711–714.                                                            |   |
| 12. Ayus JC, Moritz ML (2010) Bone disease as a new complication of     |   |
| hyponatraemia: moving beyond brain injury. Clin J Am Soc Nephrol 5:167– |   |
| 168.                                                                     |   |
| 13. Ayus JC, Achinger SG, Arieff A (2008) Brain cell volume in           |   |
| hyponatraemia: role of sex, age, vasopressin, and hypoxia. Am J Physiol  |   |
| Renal Physiol 295:F619–F624.                                             |   |
| 14. Bosco A, Paramore C, Verbalis JG (2006) Cost of illness of           |   |
| hyponatraemia in the United States. Cost Eff Resour Alloc 4:10.           |   |
| 15. Barsony J, Manigrasso MB, Xu Q, Tam H, Verbalis JG (2013) Chronic    |   |
| hyponatraemia exacerbates multiple manifestations of senescence in male  |   |
| rats. Age 35:271–288.                                                    |   |
| 16. Verbalis JG, Barsony J, Sugimura Y, Tian Y, Adams DJ, et al. (2010)  |   |
| Hyponatraemia-induced osteoporosis. J Bone Mineral Res 25:554–563.        |   |
| 17. Renneboog B, Musch W, Vandenbergel X, Manto MU, Decaux G (2006) Mild |   |
| Chronic Hyponatraemia Is Associated With Falls, Unsteadiness, and        |   |
| Attention Deficits. Am J Med 119:71.e1–71.e8.                            |   |
| 18. Shaqiro DS, Sonnenblick M, Galperin I, Melkonyan L, Munter G (2010)  |   |
| Severe hyponatraemia in elderly hospitalized patients: Prevalence,       |   |
| aetiology and outcome. Intern Med 40:574–580.                            |   |
| 19. Clayton JA, Le Jeune IR, Hall IP (2006) Severe hyponatraemia in      |   |
| medical patients: aetiology, assessment and outcome. QJM 99:505–511.     |   |
| 20. Ayus JC, Negri AL, Kalantar-Zadeh K, Moritz ML (2012) Is chronic     |   |
| hyponatraemia a novel risk factor for hip fracture in the elderly? Nephrol |   |
| Dial Transplant 27:3275–3731.                                            |   |
| 21. Ayus JC, Wheeler JM, Arieff AI (1992) Postoperative hyponatraemic   |   |
| encephalopathy in menstruant women. Ann Intern Med 117:891–897.          |   |
| 22. Hoyle GE, Chua M, Soiza RL (2011) Volaemic assessment of the elderly |   |
| hyponatrexemic patient: reliability of clinical assessment and           |   |
| validation of bioelectrical impedance analysis. QJM 104:35–39.           |   |
| 23. Soiza RL, Hoyle GE (2011) Syndrome of appropriate antidiuretic hormone: |   |
| difficulties with diagnosing syndrome of inappropriate antidiuretic hormone in older people. Intern Med J 41:285. |   |
| 24. McPherson E, Dunsmuir RA (2002) Hyponatraemia in hip fracture patients. |   |
| Scott Med J 47:115–116.                                                  |   |
| 25. Santhu HS, Gilles E, DeVita MV, Panagopoulos G, Michelis MF (2009)    |   |
| Hyponatraemia associated with large-bone fracture in elderly patients. Int Urol 41:733–737. |   |
| 26. Kinsella S, Moran S, Sullivan MO, Molloy MGM, Eastace JA (2010)       |   |
| Hyponatraemia Independent of Osteoporosis is Associated with Fracture Occurrence. Clin J Am Soc Nephrol 5:275–280. |   |
| 27. Risholm J, Nybo H, Andersen Ranberg K, Himmelstrop B, Skjelbo E, et al. |   |
| (2002) Hyponatraemia in Very Old Nonhospitalised People: Association with Drug Use. Drugs Aging 19:685–693. |   |
| 28. Incalzi RA, Gemma A, Capparella O, Terranova L, Sanginetti C, et al. ( |   |
| 1993) Post-operative electrolyte imbalance: Its incidence and prognostic implications for elderly orthopaedic patients. Ageing 22:325–331. |   |
| 29. Gill G, Huda B, Boyd A, Skagen K, Wolfe D, et al. (2006) Characteristics and |   |
| mortality of severe hyponatraemia - a hospital-based study. Clin Endocrinol (Oxf) 65:246–249. |   |
| 30. Wald RCM, Jahe RL, Price LL, Upadhyay A, Madhav NE (2010) Impact of Hospital-Associated Hyponatraemia on Selected Outcomes. Arch Intern Med 170:294–302. |   |
| 31. Gosch M, Joosten-Gorein B, Heppner HJ, Lechleitner M (2012) Hyponatraemia in geriatric inpatient patients: effects on a comprehensive geriatric assessment. Gerontology 58:430–440. |   |
| 32. Saeed BO, Beaumont D, Handley GH, Weaver JU (2002) Severe hyponatraemia: investigation and management in a district general hospital. J Clin Pathol 55:953–966. |   |
| 33. Hoorn EJ, Rivadeneira F, van Meurs JB, Ziere G, Stricker BH, et al. ( |   |
| 2011) Mild hyponatraemia as a risk factor for fractures: the Rotterdam Study. J Bone Miner Res 26:1822–1828. |   |
| 34. Mann SJ (2008) The silent epidemic of thiazide-induced hyponatraemia. J Clin Hypertens (Greenwich) 10:477–484. |   |
| 35. Clayton JA, Rodgers S, Blackey J, Avery A, Hall IP (2006) Thiazide diuretic prescription and electrolyte abnormalities in primary care. Br J Clin Pharmacol 61:37–45. |   |
| 36. Hamzat H, Sun H, Ford JC, MacLeod J, Soiza RL, et al. (2012) Inappropriate |   |
| Prescribing of Proton Pump Inhibitors in Older Patients Effects of an Educational Strategy. Drugs Aging 29:681–690. |   |
| 37. Durst RP, Pipek R, Levy Y (1994) Hyponatraemia caused by omeprazole treatment. Am J Med 97:400–401. |   |
| 38. Wilkinson TJ, Begg RJ, Winter AC, Sainsbury R (1999) Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly people. Br J Clin Pharmacol 47:211–217. |   |
| 39. Movig KLL, Leufkens HGM, Lenderink AW, Van Den Akker V, Hodiamont PPG, et al. (2002) Association between antidepressant drug use and hyponatraemia: a case-control study. Br J Clin Pharmacol 53:363–369. |   |
| 40. Chung HM, Kluge R, Schier R, Anderson RJ (1986) Postoperative        |   |
| Hyponatraemia A Prospective Study. Surv Anesthesiol 36:292.               |   |
| 41. Verbalis JG, Goldsmith SR, Greenberg A, Schier RW, Sterns RH (2007) Hyponatraemia Treatment Guidelines 2007: Expert Panel Recommendations. Am J Med 120:81–821. |   |